Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
IMNM 
Immunome Inc (IMNM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: IMNM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $25.67
1 Year Target Price $25.67
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.14% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.79B USD | Price to earnings Ratio - | 1Y Target Price 25.67 |
Price to earnings Ratio - | 1Y Target Price 25.67 | ||
Volume (30-day avg) 9 | Beta 2.18 | 52 Weeks Range 5.15 - 20.80 | Updated Date 12/14/2025 |
52 Weeks Range 5.15 - 20.80 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2137.1% |
Management Effectiveness
Return on Assets (TTM) -46.48% | Return on Equity (TTM) -93.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1526144120 | Price to Sales(TTM) 185.43 |
Enterprise Value 1526144120 | Price to Sales(TTM) 185.43 | ||
Enterprise Value to Revenue 157.68 | Enterprise Value to EBITDA -0.72 | Shares Outstanding 91710277 | Shares Floating 75173997 |
Shares Outstanding 91710277 | Shares Floating 75173997 | ||
Percent Insiders 9.45 | Percent Institutions 98.98 |
About Immunome Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 2020-10-02 | Chairman, President & CEO Dr. Clay B. Siegall Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 168 | Website https://immunome.com |
Full time employees 168 | Website https://immunome.com | ||
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.